Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Igor Stukalin(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Naveen S. Basappa, Ziad Bakouny(Dana-Farber Cancer Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Frede Donskov(Aarhus University Hospital), Chun Loo Gan(University of Calgary), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Nazlı Dizman(City Of Hope National Medical Center), Guillermo de Velasco(Dana-Farber Cancer Institute), Shaan Dudani(William Osler Health System), Christina M. Canil(University of Ottawa), Thomas Powles(National Health Service), Neeraj Agarwal(University of Utah), Ulka N. Vaishampayan(University of Michigan), Aaron R. Hansen(Princess Margaret Cancer Centre)
Cited by 8
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k